Nasal cell test may predict cystic fibrosis drug success
NCT ID NCT03894657
First seen Jan 11, 2026 · Last updated May 12, 2026 · Updated 23 times
Summary
This study looked at whether a test using cells from the nose can predict if the drug Orkambi will improve lung function in people with cystic fibrosis. 91 participants with a specific genetic mutation (F508del) took Orkambi for up to 48 weeks. The goal was to see if the lab test matched real-world breathing improvements.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Necker-Enfants Malades
Paris, Île-de-France Region, 75015, France
Conditions
Explore the condition pages connected to this study.